查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1189816

瓣环成形术系统市场——增长、趋势和预测 (2023-2028)

Annuloplasty System Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，瓣环成形术系统市场的复合年增长率预计为 4.2%。

COVID-19 大流行对瓣膜成形术系统市场产生了重大影响。 严格的封锁和政府法规减少了心臟手术的数量。 在大流行期间，用于心臟修復手术的瓣环成形术系统使到医院和诊所接受手术的患者人数显着下降。

例如，2022 年 2 月，发表在国家医学图书馆杂誌上的一篇文章发现，印度在大流行期间选择二尖瓣修復术的患者数量大幅下降。 此外，2022 年 3 月发表在国家医学图书馆杂誌上的一篇论文发现，在 COVID-19 的第一次激增期间，美国的心臟手术数量急剧下降。 因此，COVID-19 爆发对其前身的市场增长产生了负面影响。 然而，在大流行后的情况下，它有望成为市场的推动力。

此外，老年人口的增加、开发可生物降解瓣环成形术系统的技术进步、越来越多地使用瓣环成形术系统修復主动脉瓣等是推动市场增长的一些主要因素。我们就是其中之一。 目前对血管成形术等微创手术的需求不断增长。 例如，根据美国心臟协会2022年1月发布的心脏病和中风统计数据，美国冠状动脉疾病的患病率约为7.2%，估计急性心肌梗死（AMI）的年发病率预计为到 2022 年上升。估计每 1,000 人中有 3.7 人。

瓣膜反流是一种常见于老年人的心臟瓣膜疾病，可由感染或组织退化引起。 血液渗入心臟深处，疾病就会恶化。 在这种情况下，如果不进行瓣环成形术或瓣膜置换术，心臟可能会受到永久性损伤。 此外，根据世界银行2022年发布的数据，2020年英国65岁及以上人口将达到18.65%，而2021年为18.85%。 预计这一数字将继续增加。 因此，老年人口的增加可能导致需要治疗循环性出血的心血管疾病的增加。 预计这些因素将在预测期内推动市场增长。

此外，市场主要参与者的新产品发布和战略活动对市场增长产生了积极影响。

例如，2021 年 1 月，经导管二尖瓣和三尖瓣修復和置换解决方案的开发商 Valcare Medical 宣布，它已经完成了 AMEND 瓣环成形术环的首次人体经房间隔递送。我来了。 此外，2021 年 1 月，Micro Interventional Devices, Inc. 向公告机构提交了用于三尖瓣修復的 MIA-TTM 经皮三尖瓣瓣环成形术系统获得 CE 标誌批准所需的技术文件。正在宣布。 因此，由于产品发布和合作伙伴关係，预计在预测期内市场将显着增长。

因此，由于上述因素，预计所研究的市场将继续增长。 然而，循环出血的高成本和熟练专业人员的短缺可能会阻碍市场增长。

主要市场趋势

二尖瓣修復预计在预测期内增长

二尖瓣修復术是一种修復或更换心臟渗漏或僵硬的二尖瓣的手术。 二尖瓣位于左心室（左心房和左心室）之间。 二尖瓣修復可以通过心臟直视手术或微创心臟手术（瓣环成形术）来完成。 二尖瓣修復术最受医生青睐，因为它对心臟的压力较小。 此外，根据 2021 年 6 月发表在 BMJ 杂誌上的一篇论文，二尖瓣瓣环成形术治疗继发性心房二尖瓣反流后的预后与总体死亡率和二尖瓣反流有关。案例研究表明一个有利的结果，反映在瓣膜关闭不全的低復发率上。 由于二尖瓣成形术是最受医生青睐的治疗方法，因此有望在目标患者中普及，成为未来市场扩张的推动力。

此外，根据 2022 年 6 月发表在国家医学图书馆杂誌上的一篇论文，对心脏病患者进行了个案研究。 这项研究表明，二尖瓣修復术的围手术期死亡率低于二尖瓣置换术。 因此，二尖瓣修復相对于其他外科手术的日益优越性为该领域的未来增长创造了机会。

此外，市场主要参与者正在进行的研发活动对该细分市场的增长产生了积极影响。 例如，2021 年 4 月，市场领先的医疗技术和创新公司 LivaNova PLC 推出了美国 FDA 批准的增强心肌功能并减缓低射血性心力衰竭进展的突破性设备计划。宣布第 300 例随机化自主神经调节疗法 (ANTHEM-HFrEF) 关键试验中的患者。 此外，2021 年 9 月，Affluent Medical 宣布首次成功调整 Carios 二尖瓣环，该患者患有復发性严重术后二尖瓣反流。我来了。

因此，由于上述因素，预计二尖瓣修復领域在预测期内将出现显着增长。

北美引领角膜成形术市场

由于技术先进的产品随时可用以及患者对瓣膜修復手术和瓣膜成形术的高度认识，北美在市场上占据主导地位。 美国老年人口的增加是促进北美研究市场增长的关键因素之一。

例如，根据经济合作与发展组织（OECD）2022年发布的数据，2021年美国65岁及以上人口比例增至16.83%。 此外，根据人口事务研究所的数据，美国人口正在老龄化，男女之间的预期寿命差距正在缩小。 这些统计数据表明，该地区不断增长的老年人口预计将推动该国的市场增长。

综上所述，北美市场有望扩大。

竞争格局

随着主要参与者在某些细分市场站稳脚跟，瓣环成形术系统市场正在整合。 竞争格局包括对少数具有市场份额的知名国际和本地公司的分析。 其中包括美敦力、雅培、Edwards Lifesciences Corporation、波士顿科学公司、Affluent Medical、BioStable Science & Engineering、LivaNova PLC、Coroneo、Genesee BioMedical、Medtentia International Ltd Oy、Micro Interventional Devices Incorporated、Valcare Medical。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 不断增长的老年人口
    • 可生物降解瓣环成形术系统开发的技术进步
    • 越来越多地使用瓣环成形术系统进行主动脉瓣修復
  • 市场製约因素
    • 血管成形术的高昂费用
    • 缺乏熟练的专业人员
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 通过申请
    • 二尖瓣修復
    • 三尖瓣修復
    • 主动脉瓣修復
  • 最终用户
    • 医院
    • 门诊手术中心
    • 专科诊所
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 世界其他地方

第六章竞争格局

  • 公司简介
    • Medtronic
    • Abbott
    • Edwards Lifesciences Corporation
    • Boston Scientific Corporation
    • Affluent Medical
    • BioStable Science & Engineering
    • LivaNova PLC
    • Coroneo
    • Genesee BioMedical
    • Medtentia International Ltd Oy
    • Micro Interventional Devices Incorporated
    • Valcare Medical

第7章 市场机会与今后动向

简介目录
Product Code: 92949

The annuloplasty system market is expected to register a CAGR of 4.2% during the forecast period.

The COVID-19 pandemic had a substantial impact on the annuloplasty system market. The strict lockdowns and government regulations resulted in a decrease in the number of cardiac surgeries. The annuloplasty system is used in heart repair surgeries, and during the pandemic, the number of patients going to hospitals or clinics for surgeries decreased significantly.

For instance, according to an article published by the journal of the National Library of Medicine in February 2022, there was a significant drop in the number of patients opting for mitral valve repair during the pandemic in India. Furthermore, according to an article published in the journal of the National Library of Medicine in March 2022, the cardiac surgery volume decreased dramatically during the first surge of COVID-19 in United States. Thus, the COVID-19 outbreak negatively affected the market's growth in its preliminary phase. However, the market is expected to gain traction in the post-pandemic scenario.

Further, the rising geriatric population, technological advancements in the development of biodegradable annuloplasty systems, and increasing use of annuloplasty systems for aortic valve repair are among the major factors driving the growth of the market. Currently, the demand for minimally invasive procedures like annuloplasty is increasing. For instance, according to the heart disease and stroke statistics released by the American Heart Association in January 2022, the prevalence of coronary heart disease was around 7.2% in United States, and an estimated yearly incidence of acute myocardial infarction (AMI) is 3.7 in 1,000 individuals in 2022.

Heart valve regurgitation is a common heart valve disease in the elderly that may be caused by an infection or degeneration of the tissues. It causes blood to leak backward into the heart, and the condition is progressive. Annuloplasty or valve replacement must be done in such cases, or the heart can be permanently damaged. Moreover, according to the data published by Worldbank in 2022, 18.85% of the population in United Kingdom was aged more than 65 years in 2021, whereas 18.65% in 2020. This number is expected to increase in the future. Therefore, the rising geriatric population will increase the number of cardiovascular diseases that need annuloplasty treatment. These factors are expected to drive the growth of the market in the forecast period.

In addition, new product launches and strategic activities by major players in the market are positively affecting the market's growth.

For instance, in January 2021, Valcare Medical, developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announced that they had completed their first-in-human trans-septal delivery of the AMEND annuloplasty ring. Additionally, in January 2021, Micro Interventional Devices Incorporated announced that they had submitted the required technical documentation for CE Mark approval for its MIA-TTM Percutaneous Tricuspid Annuloplasty System for tricuspid valve repair to its notified body. Thus, due to product launches and partnerships, the market is expected to grow significantly in the forecast period.

Therefore, owing to the aforementioned factors, the market studied is anticipated to witness growth. However, the high cost of annuloplasty and the lack of skilled professionals are likely to impede the market growth.

Key Market Trends

Mitral Valve Repair is Expected to Witness Growth During the Forecast Period

Mitral valve repair is a type of surgery to fix or replace a leaky or stiff mitral valve in the heart. The mitral valve is between the left heart chambers (left atrium and left ventricle). Mitral valve repair may be done as open-heart or minimally invasive heart surgery (annuloplasty). Mitral valve repair is most commonly preferred by doctors as it puts less stress on the heart. Moreover, according to an article published in BMJ Journal in June 2021, a case study suggested that the prognosis following mitral valve annuloplasty to treat atrial secondary mitral regurgitation is good, as reflected by lower all-cause mortality and mitral regurgitation recurrence. As doctors most commonly prefer mitral valve repair, the adoption of this procedure is likely to increase among the target population, ultimately driving market growth.

In addition, according to an article published in the journal of the National Library of Medicine in June 2022, a case study was performed on heart disease patients. The study showed that mitral valve repair had lower perioperative mortality than mitral valve replacement. Thus, the increasing advantages of mitral valve repair over other procedures are creating opportunities for future growth of the segment.

Furthermore, continuous R&D activities by major players in the market are positively affecting the segment's growth. For instance, in April 2021, LivaNova PLC, a market-leading medical technology and innovation company, announced that they had randomized the 300th patient in the autonomic regulation therapy to enhance myocardial function and reduce the progression of heart failure with reduced ejection fraction (ANTHEM-HFrEF) pivotal study, which United States FDA approved under the Breakthrough Devices Program. Further, in September 2021, Affluent Medical announced the success of the first-ever Kalios mitral ring adjustment on a patient suffering from a post-operative recurrence of severe mitral insufficiency.

Therefore, the mitral valve repair segment is expected to witness significant growth during the forecast period due to the abovementioned factors.

North America is Dominating the Annuloplasty System Market

North America is dominating the market owing to factors such as the easy availability of technologically advanced products and high awareness among patients about valve repair surgeries or annuloplasty. An increase in the geriatric population in United States is among the key factors contributing to the growth of the market studied in North America.

For instance, according to the data from Organisation for Economic Co-operation and Development (OECD) published in 2022, the population aged 65 or older as a percentage of the total population increased to 16.83% in 2021 in United States. Furthermore, according to Population Reference Bureau, United States population is growing older, and the gender gap in life expectancy is narrowing. These statistics suggest that the rising geriatric population in the region is anticipated to drive market growth in the country.

Therefore, owing to the aforementioned factors, the market's growth is anticipated in the North America Region.

Competitive Landscape

The annuloplasty system market is consolidated as the major players have established themselves in specific market segments. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. This includes Medtronic, Abbott, Edwards Lifesciences Corporation, Boston Scientific Corporation, Affluent Medical, BioStable Science & Engineering, LivaNova PLC, Coroneo, Genesee BioMedical, Medtentia International Ltd Oy, Micro Interventional Devices Incorporated, Valcare Medical among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population
    • 4.2.2 Technological Advancements in the Development of Biodegradable Annuloplasty Systems
    • 4.2.3 Increasing Use of Annuloplasty Systems for Aortic Valve Repair
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Annuloplasty
    • 4.3.2 Lack of Skilled Professionals
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Application
    • 5.1.1 Mitral Valve Repair
    • 5.1.2 Tricuspid Valve Repair
    • 5.1.3 Aortic Valve Repair
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Specialty Clinics
    • 5.2.4 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Medtronic
    • 6.1.2 Abbott
    • 6.1.3 Edwards Lifesciences Corporation
    • 6.1.4 Boston Scientific Corporation
    • 6.1.5 Affluent Medical
    • 6.1.6 BioStable Science & Engineering
    • 6.1.7 LivaNova PLC
    • 6.1.8 Coroneo
    • 6.1.9 Genesee BioMedical
    • 6.1.10 Medtentia International Ltd Oy
    • 6.1.11 Micro Interventional Devices Incorporated
    • 6.1.12 Valcare Medical

7 MARKET OPPORTUNITIES AND FUTURE TRENDS